Axsome Therapeutics (AXSM) EBIT (2015 - 2026)
Axsome Therapeutics (AXSM) reported EBIT of -$63.4 million for Q1 2026, down 11.19% on a YoY basis from -$71.3 million in Q1 2025, and down 135.03% sequentially from -$27.0 million in Q4 2025.
Axsome Therapeutics (AXSM) EBIT (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of EBIT data on file, last reported at -$63.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 11.19% year-over-year to -$63.4 million; the trailing twelve-month figure through Mar 2026 stood at -$173.1 million (up 35.94% YoY), and the FY2025 full-year result was -$166.8 million, up 40.56% from the prior year.
- EBIT retreated to -$63.4 million in Q1 2026, from -$27.0 million in the prior quarter.
- In the past five years, EBIT ranged from a high of -$6.4 million in Q1 2023 to a low of -$98.3 million in Q4 2023.
- A 5-year average of -$54.3 million and a median of -$59.9 million in 2022 frame the typical range for EBIT.
- Across the five-year window, EBIT soared 83.35% in 2023 and sank 955.46% in 2024, its largest moves.
- Tracing AXSM's EBIT over 5 years: stood at -$59.9 million in 2022, then sank by 64.01% to -$98.3 million in 2023, then gained by 26.11% to -$72.6 million in 2024, then soared by 62.88% to -$27.0 million in 2025, then tumbled by 135.03% to -$63.4 million in 2026.
- Business Quant data shows AXSM's EBIT at -$63.4 million in Q1 2026, -$27.0 million in Q4 2025, and -$46.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Axsome Therapeutics | 12.37 Bn | 12.06 Bn | 176.48 Mn | -63.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.36 Mn |
| Dec 31, 2025 | -26.96 Mn |
| Sep 30, 2025 | -46.11 Mn |
| Jun 30, 2025 | -36.71 Mn |
| Mar 31, 2025 | -56.98 Mn |
| Dec 31, 2024 | -72.62 Mn |
| Sep 30, 2024 | -62.62 Mn |
| Jun 30, 2024 | -78.05 Mn |
| Mar 31, 2024 | -67.28 Mn |
| Dec 31, 2023 | -98.27 Mn |
| Sep 30, 2023 | -62.12 Mn |
| Jun 30, 2023 | -65.06 Mn |
| Mar 31, 2023 | -6.37 Mn |
| Dec 31, 2022 | -59.92 Mn |
| Sep 30, 2022 | -42.41 Mn |
| Jun 30, 2022 | -39.18 Mn |
| Mar 31, 2022 | -38.29 Mn |
| Dec 31, 2021 | -32.61 Mn |
| Sep 30, 2021 | -33.41 Mn |
| Jun 30, 2021 | -30.85 Mn |